Clinical trials
Immunotherapy clinical trials
Below are recruiting immunotherapy clinical trials, each written for real people, not researchers. We’re tracking 769 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04671667RecruitingPhase 2
Pembrolizumab vs chemo-radiation after surgery for recurrent head/neck cancer
This trial tests whether pembrolizumab (an immunotherapy drug) works better than the usual chemo plus radiation after surgery for cancer that has come back in the head and neck area. It may help reduce cancer returning or spreading by using your immune system, but eligibility depends on how the cancer came back and your prior treatments.
Birmingham, AlabamaAges 18–79 - NCT04681469RecruitingPhase 2
Niraparib plus immunotherapy for HPV-negative head and neck cancer
This Phase 2 study tests a cancer “induction then maintenance” plan using a PARP inhibitor (niraparib) along with immunotherapy (TSR-042) in people with HPV-negative head and neck squamous cell cancer. If it works, it may improve control of the cancer after surgery by boosting the immune system and targeting cancer cells’ DNA repair.
BresciaAges 18 years+ - NCT04686305RecruitingPhase 1
Test drug T-DXd plus immunotherapy, with or without chemotherapy for HER2+ lung cancer
This Phase 1 study tests the safety (and early effectiveness) of T-DXd combined with immunotherapy, sometimes also with chemotherapy, in people with advanced lung cancer that is HER2-positive. It may help if standard options have been limited or your tumor does not have certain genetic changes that already have targeted treatments.
Duarte, CaliforniaAges 18 years+ - NCT04728724RecruitingPhase 2
Check immune treatment before surgery for stage III lung cancer
This Phase 2 trial tests an “immunotherapy” medicine given before surgery for stage III non-small cell lung cancer. The goal is to shrink the cancer and make curative surgery more successful while monitoring safety and response.
ShanghaiAges 18–75 - NCT04761328Recruiting
Study fear of cancer coming back and stopping immunotherapy
This study looks at fear of cancer coming back and how people feel about stopping immunotherapy (cancer treatment that helps the immune system). You may be able to join if you’re an adult with a cancer history that included immunotherapy, and if you can safely participate.
Pittsburgh, PennsylvaniaAges 21 years+ - NCT04777175Recruiting
Looking at immunotherapy for lung cancer with rare gene mutations
This study looks back at patients with advanced non-small cell lung cancer who have specific rare gene changes (mutations). It aims to see how well immunotherapy works for people with these exact mutations.
Changsha, HunanAges 18–75 - NCT04807114Recruiting
Blood or tissue testing to find markers for lung cancer treatment
This study uses detailed “single-cell” testing to look for markers that can predict how well immunotherapy works and what side effects may happen. It is for people with non-small cell lung cancer starting standard first-line treatment.
LeuvenAges 18–120 - NCT04807127Recruiting
Testing blood and lung fluid markers for lung side effects
This study tries to find early warning markers in lung fluid collected during a bronchoscopy (a camera test of the airways). The goal is to better spot and understand lung inflammation that can happen after immune checkpoint cancer treatments.
Leuven, Flemish BrabantAges 18–120 - NCT04913311Recruiting
Testing markers to predict lung inflammation after lung cancer treatment
This study looks for early “predictive markers” to tell who is most likely to develop lung inflammation after standard treatment for non-small cell lung cancer. It may help clinicians spot problems sooner and tailor care, using additional monitoring during treatment.
Houston, TexasAges Any age - NCT04926584Recruiting
Immunotherapy for advanced or limited-spread lung cancer
This trial tests whether starting immunotherapy can help people with newly diagnosed advanced or limited-spread non-small cell lung cancer that cannot be fully cured with standard local treatments. It may offer a new treatment approach when surgery or definitive chemoradiation isn’t a good option.
Esslingen am NeckarAges 18 years+ - NCT04958720Recruiting
Registry for esophagus and stomach cancer patients
This study keeps an organized record of people diagnosed with esophagus, gastroesophageal junction, or stomach cancer. It helps researchers learn from real-world outcomes, based on health information collected over time.
Alicante, AlicanteAges 18–100 - NCT04972942RecruitingPhase 1
Immunotherapy for high-risk T-cell blood cancers after transplant
This Phase 1 study tests a targeted immune treatment given after strong pre-treatment (myeloablative chemo plus total-body radiation) before or along with an allogeneic stem cell transplant. It may help prevent the cancer from coming back in young people with high-risk T-cell ALL or certain T-cell lymphomas.
Phoeniz, ArizonaAges Up to 39 years - NCT04973306RecruitingPhase 2/Phase 3
Chemo-immunotherapy before surgery versus chemo-radiation
This trial compares adding immunotherapy to standard chemo-radiation before surgery for locally advanced, operable esophageal squamous cell cancer. It aims to improve how well the tumor responds and whether patients do better after surgery.
ShanghaiAges 18–75 - NCT04977375RecruitingPhase 1/Phase 2
Anti–PD-1 treatment plus focused radiation for recurrent glioblastoma
This trial tests a cancer-immunotherapy medicine (an anti–PD-1 antibody, similar to pembrolizumab) combined with precisely targeted radiation to treat glioblastoma that has come back or progressed. It may help your immune system recognize and attack the tumor while the radiation targets the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT04988945RecruitingPhase 2
Immunotherapy with liver tumor radiation to shrink hard-to-remove liver cancer
This Phase 2 trial tests whether combining targeted liver procedures (TACE) and high-dose radiation (SBRT) followed by two immunotherapy drugs can “downstage” hepatocellular carcinoma (HCC), meaning make it smaller/less advanced. It may help some people become better candidates for future treatment by shrinking tumors.
Hong KongAges 18 years+ - NCT04999943RecruitingPhase 1
Testing two blood-cancer medicines plus eDC in older MDS patients
This early-phase study tests a combination of two standard medicines for myelodysplastic syndrome (MDS) along with an added eDC therapy in people age 60 and older. It may help improve blood counts or disease control for those who cannot or do not want stem cell transplant.
BeijingAges 60 years+ - NCT05027633RecruitingPhase 2
Immunotherapy plus chemo and radiation for nasal cancer
This Phase 2 study tests a treatment plan that combines immunotherapy with chemotherapy and chemoradiation for advanced squamous cell cancer in the nasal cavity or sinuses. It aims to improve cancer control in people who are newly diagnosed and have not had prior treatment for this cancer.
Houston, TexasAges 18 years+ - NCT05029531RecruitingPhase 3
Immuno-chemotherapy for infants with B-lineage ALL
This trial tests a combination of medicines (immunotherapy plus chemotherapy) in babies diagnosed with a type of leukemia called B-lineage acute lymphoblastic leukemia (ALL). It aims to improve how well treatment works and is delivered safely in very young children.
Moscow, Samory-Mashela,1Ages 1 day–12 months - NCT05039632RecruitingPhase 1/Phase 2
NBTXR3 plus radiation with anti-PD-1 for advanced lung or liver cancers
This study tests whether adding NBTXR3 (given into a tumor) and targeted radiation to anti–PD-1/PD-L1 immunotherapy can improve cancer control in advanced cancers that have spread to the lung and/or liver. Participants may be assigned to different radiation approaches to try to trigger tumor shrinkage in both treated and nearby or distant tumor areas.
Houston, TexasAges 18 years+ - NCT05085028RecruitingPhase 3
Lower-dose pembrolizumab for lung cancer after 6 months
This trial studies whether giving pembrolizumab less often can work just as well for advanced non-small cell lung cancer after you’ve already had 6 months of treatment and are still benefiting. It may help reduce how often you need treatment while keeping cancer control.
BournemouthAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT05106296RecruitingPhase 1
Chemo-immunotherapy with ibrutinib and indoximod for pediatric brain tumors
This Phase 1 study tests a combination treatment (ibrutinib plus indoximod along with chemotherapy) for children with brain tumors that have come back or are hard to treat. It may help shrink active tumor or control the disease when standard treatments can’t cure it.
Augusta, GeorgiaAges 3–25 - NCT05142475RecruitingEarly Phase 1
Study of GC101 tumor-infiltrating cells for advanced breast cancer
This early-phase study tests an experimental cell therapy made from your tumor’s immune cells (TILs) for advanced breast cancer. It may help shrink tumors or improve how long people stay in remission, but it’s still being studied for safety and effectiveness.
ShanghaiAges 18–75 - NCT05173272RecruitingPhase 3
Immunotherapy plus chemo, then radiation, for advanced cervical cancer
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
Chengdu, SichuanAges 18 years+
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunotherapy?
- Yes. Clin2 currently lists 769 recruiting immunotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.